A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Trial Profile

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Niraparib (Primary) ; Antineoplastics; Capecitabine; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms BRAVO
  • Sponsors TESARO
  • Most Recent Events

    • 27 Feb 2018 According to a TESARO media release, the Company expects to publish data from this trial in 2H 2018.
    • 31 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 May 2018.
    • 31 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top